In 428 patients after curative-intent treatment of colorectal cancer liver metastases, aspirin 160 mg daily did not improve disease-free survival versus placebo (HR 1·08; p=0·51); 36-month overall survival was lower with aspirin (76% vs 85%).
RCTn = 428
Yaqub et al. Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial